Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis

Journal of Medicinal Chemistry

Volumn 44, Issue 22, 2001, Pages 3730-3745

  Duffy, K J ^a   Darcy, M G ^a   Delorme, E ^b   Dillon, S B ^a   Eppley, D F ^a   Erickson Miller, C ^a   Giampa, L ^b   Hopson, C B ^a   Huang, Y ^a   Keenan, R M ^a   Lamb, P ^b   Leong, L ^a   Liu, N ^a   Miller, S G ^b   Price, A T ^a   Rosen, J ^b   Shah, R ^a   Shaw, T N ^a   Smith, H ^b   Stark, K C ^a   Tian, S S ^b   Tyree, C ^b   Wiggall, K J ^a   Zhang, L ^a   Luengo, J I ^a   more..

^a GLAXOSMITHKLINE   (United States)

^b LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 DIAZO 3 HYDROXY 1 NAPHTHALENESULFONIC ACID; AZONAPHTHALENE; HYDRAZINE DERIVATIVE; HYDRAZINONAPHTHALENE; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MEGAKARYOPOIESIS; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; REPORTER GENE; STRUCTURE ACTIVITY RELATION;

ANIMALS; AZO COMPOUNDS; CELL DIVISION; CELL LINE; DRUG EVALUATION, PRECLINICAL; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME ACTIVATION; GENES, REPORTER; HYDRAZINES; LUCIFERASES; MEGAKARYOCYTES; MICE; MOLECULAR MIMICRY; MOLECULAR WEIGHT; NAPHTHALENESULFONATES; NEOPLASM PROTEINS; PHOSPHORYLATION; PHOSPHOTRANSFERASES; PROTO-ONCOGENE PROTEINS; PYRAZOLES; RECEPTORS, CYTOKINE; RECEPTORS, THROMBOPOIETIN; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBOPOIETIN;

EID: 0035950101     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm010283l     Document Type: Article

References (56)

1. Stimulation of platelet production by serum of platelet-depleted rats
2. Thrombopoietin from human embryonic kidney cells is the same factor as c-mpl-ligand
3. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin
4. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand
5. The glycan domain of thrombopoietin enhances its secretion
6. Thrombopoietin signal transduction requires functional JAK2, not TYK2
7. Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets
8. Thrombopoietin-induced activation of the mitogen-activated protein kinase (MAPK) pathway in normal megakaryocytes: Role in endomitosis
9. Cytokines in idiopathic thrombocytopenic purpura (ITP)
10. HCV-associated thrombocytopenia: Clinical characteristics and platelet response after recombinant alpha2b-interferon therapy
11. Heparin-induced thrombocytopenias
12. HIV-related thrombocytopenias
13. Thrombocytopenia associated with liver cirrhosis and hepatitis C viral infection: Role of thrombopoietin
14. Platelet transfusions: Utilization and associated costs in a tertiary care hospital
15. The annual cost of blood transfusions in the United Kingdom
16. Risks, costs, and alternatives to platelet transfusions
17. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): Cost analysis and complications
18. Use of thrombopoietic growth factors in acute leukemia
19. Current issues with platelet transfusion in patients with cancer
20. Optimal dosing and triggers for prophylactic use of platelet transfusions
21. Safety and cost-effectiveness of a 10 x 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10(9)/L trigger: A prospective comparative trial in 105 patients with acute myeloid leukemia
22. Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases
23. Successful treatment of platelet transfusion refractoriness: The use of platelet transfusions matched for both human leucocyte antigens (HLA) and human platelet alloantigens (HPA) in alloimmunized patients with leukaemia
24. Alloimmune refractoriness to platelet transfusions
25. Alloimmunization following platelet transfusion: The absence of a dose- response relationship
26. The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets
27. Use of single donor platelets
28. Oprelvekin (Neumega), first platelet growth factor for thrombocytopenia
29. Thrombopoietin: An update on therapeutic potential
30. Pegylated recombinant megakaryocyte growth and development factor
31. A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor
32. Luciferase assay: A rapid and sensitive method for the quantitation of transcriptional activity
33. Assays for transcriptional activity based on the luciferase reporter gene
34. Biochemical approaches to discovering modulators of the JAK-STAT pathway
35. Drug discovery using receptors that modulate gene expression
36. The role of JAKs and STATs in transcriptional regulation by cytokines
37. Evaluation of stability constants of metal complexes with sulfonated azo-ligands
38. Reactions of eriochrome blue black R.
39. The role of the gut flora in the metabolism of prontosil and neoprontosil in the rat
40. Structural basis of the mutagenicity of 1-amino-2-naphthol-based azo dyes
41. Biliary excretion of some azo dyes related to tartrazine
42. Structural studies of arylazo and arylimino compounds. Nitrogen-15 NMR and x-ray crystallographic studies of azo-hydrazo tautomerism
43. CI Pigment Yellow 10, 4-[2′,5′-(dichlorophenyl)-hydrazono]-5- methyl-2-phenyl-3H-pyrazol-3-one
44. CI Pigment Yellow 60, 4-(2-chlorophenylhydrazono)-3-methyl-1-phenyl-5-pyrazolone
45. CI pigment yellow 74,. alpha. -(2-methoxy-4-nitrophenylhydrazono)-. alpha. -aceto-2′-methoxyacetanilide
46. CI pigment yellow 65, alpha. -(4-methoxy-2-nitrophenylhydrazono)-. alpha. -aceto-2′-methoxyacetanilide
47. Study of tautomerism in arylazopyrazolones and related heterocycles with nuclear magnetic resonance spectroscopy
48. The structure of some 5-pyrazolones and derived 4-arylazo-5-pyrazolones
49. The direct introduction of the Diazonium Group. Part VII. The coupling of toluene-p-sulphonazide with phenoxide ions to yield diazo-oxides
50. The constitution of internal diazooxides (diazophenols). Part II
51. Naphth[1,2-d]oxazole intermediates in the preparation of 3-hydroxy-4-(l-alkyl-3-methyl-5-hydroxy-4-pyrazolylazo)- 1-naphthalenesulfonamide dyes
52. Synthesis and biological evaluation of naphthyldesferrithiocin iron chelators
53. The mercuration of naphthalic acids
54. The effect of substituents on the pKa values of "meta"-substituted 1- and 2-naphthols
55. Establishment and characterization of the thrombopoietin-dependent megakaryocytic cell line, UT-7/TPO